Dr John Gray Phillips, MD | |
224 Malibu Cv, Barefoot Beach, FL 34134-8536 | |
(239) 948-2751 | |
Not Available |
Full Name | Dr John Gray Phillips |
---|---|
Gender | Male |
Speciality | Neurological Surgery |
Location | 224 Malibu Cv, Barefoot Beach, Florida |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1659638815 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207T00000X | Neurological Surgery | MD014325E (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr John Gray Phillips, MD 224 Malibu Cv, Barefoot Beach, FL 34134-8536 Ph: (239) 948-2751 | Dr John Gray Phillips, MD 224 Malibu Cv, Barefoot Beach, FL 34134-8536 Ph: (239) 948-2751 |
News Archive
For the first time researchers are getting a detailed look at the interior of human coronary arteries, using an optical imaging technique developed at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH).
Professor Dr. Michael Ristow's team along with Japanese colleagues from universities in Oita and Hiroshima have demonstrated by two independent approaches that even a low concentration of lithium leads to an increased life expectancy in humans as well as in a model organism, the roundworm Caenorhabditis elegans.
The American Society of Anesthesiologists (ASA) and Iowa Society of Anesthesiologists (ISA) today launched a public education campaign to help put the minds of Iowa residents at ease about surgical procedures and the associated risks of anesthesia.
The first mental health study of Black communities in Canada has found the majority of Black Canadians display severe depressive symptoms - women, even more so - with racial discrimination confirming the appearance of these signs for nearly all.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
› Verified 5 days ago